- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03069950
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, United States, 10604
- Memoral Sloan Kettering Westchester
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed by the enrolling institution.
- Patients must have a primary L sided colorectal cancer, (at or distal to the splenic flexure)
- Confirmed RAS/RAF wild type tumor. Paraffin-embedded tumor tissue obtained from the primary tumor or metastasis
Have received prior treatment for metastatic disease with oxaliplatin-based regimen and either
- Had disease progression OR
- Had stable disease OR
- Discontinued oxaliplatin due to neuropathy
Patients must meet the following criteria for unresectability as determined by two hepatobiliary surgeons and one radiologist:
- When a margin negative resection would require resection of all three hepatic veins, both portal veins, or the retrohepatic vena cava.
Requiring a resection that leaves less than 2 hepatic segments (not including the caudate lobe) behind with adequate arterial/portal inflow, venous outflow and biliary drainage. **
**A patient is considered resectable if the procedure includes a minor wedge or thermo-ablation encompassing 10% or less of the volume of the remaining 2 segments.
- Patient"s liver metastases must comprise <70% of the liver parenchyma. All patients must be clinically fit to undergo surgery as determined by the pre-operative evaluation
Lab values within 14 days prior to enrollment/randomization:
- WBC ≥ 3.0 K/uL
- ANC > 1.5 K/uL
- Platelets ≥ 100,000/uL
- Renal function (≤ 10 days prior to enrollment/randomization) °Creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault method as follows:
Cockcroft-Gault method as follows:
- Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl x 72)
Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy regimen)
- Hepatic function, as follows: (≤ 10 days prior to enrollment/randomization)
Total Bilirubin ≤ 1.5 mg/dl
- Calcium ≥ lower limit of normal (≤ 48 hours prior to enrollment/randomization)
- KPS ≥ 60% (ECOG (or Karnofsky) performance status (preferably 0 or 1/≥ 60% for Karnofsky))
Exclusion Criteria:
- Patients < 18 years of age
- Patients who have received more than one chemotherapy regimen for metastatic disease
- Patients who are chemotherapy naïve
- Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration)
Active infection
°Active infection includes patients with positive blood cultures
- Prior treatment with HAI FUDR
- Prior TACE
- Female patients who are pregnant or lactating - or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test ≤ 72 hours before enrollment and randomization, and must have a negative pregnancy test ≤ 72 hours prior to treatment start)
- If a patient has any serious medical problems which may preclude receiving this type of treatment
- Patients with history or known presence of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded.
- Serious or non-healing active wound, ulcer, or bone fracture
- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
- Patients who have a diagnosis of Gilbert"s disease
History of other malignancy, except:
- Malignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by the treating physician
- Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAI FUDR/Dex in addition to Pmab plus FOLFIRI
Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle.
HAI pump therapy with FUDR and Dex on Day 1 of each cycle.
Patients will start protocol therapy approximately 2 weeks after surgery.
All patients will receive Panitumumab (6 mg/kg IV over 60 min).
The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
|
5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
Panitumumab (6 mg/kg IV over 60 min)
flat dose of 25 mg on Day 1
Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
|
Experimental: Pmab plus FOLFIRI alone
The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
|
5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
Panitumumab (6 mg/kg IV over 60 min)
Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resection rate assessed using RECIST (version 1.1)
Time Frame: 3 months
|
Treatment evaluation will be done using RECIST (version 1.1)
The patient will be assessed with repeat CT scans as specified.
If at any time after 3 cycles (or 3 months) the patient is able to undergo a complete resection of all hepatic metastases they will proceed to operative assessment.
|
3 months
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Dexamethasone
- Fluorouracil
- Leucovorin
- Irinotecan
- Panitumumab
- Floxuridine
Other Study ID Numbers
- 16-1341
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Adenocarcinoma Metastatic to the Liver
-
Fudan UniversityUnknownColorectal Adenocarcinoma Metastatic to the LiverChina
-
Fudan UniversityUnknownColorectal Adenocarcinoma Metastatic to the LiverChina
-
Codiak BioSciencesTerminatedAdvanced Hepatocellular Carcinoma (HCC) | Gastric Cancer Metastatic to Liver | Colorectal Cancer Metastatic to LiverUnited States
-
Ronald DeMatteo, M.D.RecruitingIntrahepatic Cholangiocarcinoma | Colorectal Cancer Metastatic to LiverUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedColorectal Cancer | Metastatic to the Liver
-
University of Wisconsin, MadisonMerck Sharp & Dohme LLCCompletedColorectal Cancer | Colorectal Adenocarcinoma | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Metastatic Carcinoma in the LiverUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the LiverUnited States
-
Provectus Biopharmaceuticals, Inc.Active, not recruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Uveal Melanoma | Metastatic Pancreatic Cancer | Metastatic Colon Cancer | Metastatic Ocular Melanoma | Cancer Metastatic to the LiverUnited States
-
UMC UtrechtNot yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer to Liver
-
Rush University Medical CenterCompletedHepatocellular Carcinoma | Metastatic Carcinoma to the LiverUnited States
Clinical Trials on Floxuridine (FUDR)
-
IRCCS San RaffaeleUnknown
-
Spectrum Health HospitalsRecruitingPancreatic Adenocarcinoma | Liver MetastasesUnited States
-
Memorial Sloan Kettering Cancer CenterWake Forest UniversityCompleted
-
NYU Langone HealthFood and Drug Administration (FDA)CompletedStomach Cancer | Gastric CancerUnited States
-
NSABP Foundation IncNational Cancer Institute (NCI)TerminatedColorectal Cancer | Metastatic CancerUnited States
-
The Netherlands Cancer InstituteErasmus Medical CenterRecruitingColorectal NeoplasmsNetherlands
-
Xu jianminRuijin Hospital; Zhejiang University; The Second Affiliated Hospital of Harbin...Unknown
-
NYU Langone HealthTerminatedGastric Cancer | Esophageal Cancer | Gastric AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingIntrahepatic CholangiocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingIntrahepatic Cholangiocarcinoma | Cholangiocellular Carcinoma | Peripheral Cholangiocarcinoma | Cholangiolar CarcinomaUnited States